1. Home
  2. AEM vs VRTX Comparison

AEM vs VRTX Comparison

Compare AEM & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Agnico Eagle Mines Limited

AEM

Agnico Eagle Mines Limited

HOLD

Current Price

$185.18

Market Cap

81.3B

Sector

N/A

ML Signal

HOLD

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

HOLD

Current Price

$525.73

Market Cap

123.4B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
AEM
VRTX
Founded
1953
1989
Country
Canada
United States
Employees
N/A
N/A
Industry
EDP Services
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
81.3B
123.4B
IPO Year
1995
2006

Fundamental Metrics

Financial Performance
Metric
AEM
VRTX
Price
$185.18
$525.73
Analyst Decision
Buy
Buy
Analyst Count
9
29
Target Price
$232.67
$539.69
AVG Volume (30 Days)
2.6M
1.3M
Earning Date
04-30-2026
05-04-2026
Dividend Yield
0.98%
N/A
EPS Growth
N/A
836.54
EPS
N/A
8.33
Revenue
N/A
$2,488,652,000.00
Revenue This Year
$43.04
$10.79
Revenue Next Year
$4.81
$10.47
P/E Ratio
$24.90
$63.58
Revenue Growth
N/A
46.20
52 Week Low
$130.04
$374.17
52 Week High
$255.24
$546.17

Technical Indicators

Market Signals
Indicator
AEM
VRTX
Relative Strength Index (RSI) 75.81 69.73
Support Level $170.97 $458.05
Resistance Level $200.64 $533.67
Average True Range (ATR) 5.21 13.58
MACD 5.17 4.96
Stochastic Oscillator 97.18 75.59

Price Performance

Historical Comparison
AEM
VRTX

About AEM Agnico Eagle Mines Limited

Agnico Eagle is a gold miner with mines in Canada, Mexico, Finland, and Australia. Agnico operated just one mine, LaRonde, as recently as 2008 before bringing its other mines online in rapid succession in the following years. It merged with Kirkland Lake Gold in 2022, acquiring the Detour Lake and Macassa mines in Canada along with the high-grade, low-cost Fosterville mine in Australia. It sold around 3.4 million gold ounces in 2025 and had about 15 years of gold reserves at end 2025. Agnico Eagle is focused on increasing gold production in lower-risk jurisdictions and bought the remaining 50% of its Canadian Malartic mine along with the Wasamac project and other assets from Yamana Gold in 2023.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: